Article
Epidermal growth factor receptor activating mutations in Spanish gefitinib-treated non-small-cell lung cancer patients.
Annals of oncology : official journal of the European Society for Medical Oncology - 1 Jul 2005
Cortes-Funes H, Gomez C, Rosell R, Valero P, Garcia-Giron C, Velasco A, Izquierdo A, Diz P, Camps C, Castellanos D, Alberola V, Cardenal F, Gonzalez-Larriba J L, Vieitez J M, Maeztu I, Sanchez J J, Queralt C, Mayo C, Mendez P, Moran T, Taron M
Abstract excerpt
BACKGROUND: North American and Japanese non-small-cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) activation via tyrosine kinase (TK) mutations respond dramatically to gefitinib treatment. To date, however, the frequency and effect of EGFR TK mutations have not been examined in European patients. PATIENTS AND METHODS: Eighty-three Spanish advanced NSCLC patients who had progressed...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.